![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Australia to Include 4 New Hepatitis C Drugs on National Formulary
Australia to Include 4 New Hepatitis C Drugs on National Formulary
![100Bills_flatmoney.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/100Bills_flatmoney.gif?t=1578960048&width=430)
March 8, 2016
Australia’s Pharmaceutical Benefits Scheme has listed four new hepatitis C drugs on its subsidized formulary.
Priced between $6.20 and $38.30 per prescription, the drugs include Gilead’s Sovaldi and Harvoni, Bristol-Myers Squibb’s Daklinza and Clinect’s ribavirin.
The drugs are available to patients over the age of 18 with chronic hepatitis C, and a complete course of treatment ranges from eight to 24 weeks, depending on the person’s genotype and treatment history.
In the U.S., Sovaldi costs roughly $1,000 per pill.
Upcoming Events
-
21Oct